Inimmune to Present on Novel Adjuvants at the 17th Vaccine Congress on September 26th, 2023
MISSOULA, MT, September 21, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a plenary presentation at the upcoming 17th Vaccine Congress in Glasgow, Scotland September 24-27th. The event brings together leading […]
Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants
Missoula, MT, October 10, 2023 – With a new NIAID contract, Pritzker Molecular Engineering Prof. Aaron Esser-Kahn will work with UChicago faculty and biotech company Inimmune Inc. to develop a flu vaccine that has fewer side effects for vulnerable populations. READ FULL ARTICLE HERE
Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company MISSOULA, Montana, August 2, 2023 – Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential […]
Inimmune to Participate at World Vaccine Congress 2023
Development of Novel STING Agonists as Vaccine Adjuvants
MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its Investigator, Omer Rasheed, Ph.D., will participate and present a poster (P087) at the upcoming ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023 in Boston entitled “Development of Novel STING Agonists as Vaccine Adjuvants” […]
Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.
MISSOULA, Montana, June 5, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will provide an update on company programs and clinical trials on May 5th at BIO International Convention in Boston, MA […]
Inimmune to Play a Key Role at the World Vaccine Congress
MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event. Dr. Evans will serve […]
